[Experimental development of immunity to pertussis]

Area of Science:

• Immunology
• Microbiology
• Vaccinology

Background:

• Bordetella pertussis (whooping cough) exhibits diverse serovars, impacting vaccine efficacy.
• Understanding serovar-specific immune responses is crucial for developing effective pertussis vaccines.

Purpose of the Study:

• To evaluate the protective potency of different Bordetella pertussis serovar sera in animal models.
• To assess the immunogenicity and efficacy of Bordetella pertussis serovar vaccines.
• To determine the optimal serovar composition for pertussis vaccinal preparations.

Main Methods:

• Animal models were intracerebrally inoculated with B. pertussis culture No 18-323, serovar 1.2.3.
• Sera from animals were tested for protective potency against different B. pertussis serovars.
• Active immunization experiments were conducted using vaccines derived from different serovars.

Main Results:

• Sera against serovar 1 strains demonstrated the highest protective potency.
• Sera against serovar 1.2 strains exhibited the lowest protective potency.
• Vaccines from serovar 1 strains were least effective, while those from serovar 1.2 strains were most immunogenic.

Conclusions:

• A discrepancy exists between the protective potency of sera and the efficacy of vaccines for B. pertussis serovar 1.
• Serovar 1 strains, in small doses, may fail to establish a stable antigenic stimulation focus.
• Vaccinal preparations should prioritize the inclusion of serovar 1.2 strains for optimal immunogenicity and efficacy.